Pharma & Bio
Technology
UBS, Which Sparked Controversy Over Alteogen Inc.’s Undervaluation, Reveals the Reason Behind Its Shift to ‘Neutral’
(Graphic: Generative AI)
Foreign securities firm UBS has withdrawn the “Sell” rating it had assigned to Alteogen Inc.(196170)after approximately one year. In its first analysis report last year, UB…
Technology
'Competition Heats Up': Can Huons Co., Ltd.'s HydiZyme Surpass Alteogen Inc.'s Tergaze?
A second product is poised to enter the domestic human recombinant hyaluronidase market. While “Tergase Injection” from Alteogen Inc.(196170)holds symbolic significance as the country’s first product,…
Technology
The Other Side of AI-Driven New Drugs… Why Hasn’t K-Bio Become “In silico”?
(Graphic: Generative AI)
A new drug candidate identified by artificial intelligence (AI) has finally entered Phase 3 clinical trials. This marks the first instance where AI was used to identify a d…
Technology
[Analysis of K-Bio M&A] Big Pharma on a Biotech Shopping Spree in China… Potential Targets for Major K-Bio M&A Deals (Part 2)
As global Big Pharma companies embark on large-scale mergers and acquisitions (M&A) to overcome the patent cliff and growth limitations, there are increasing instances of Chinese biotech companies bei…
Technology
[Analysis of K-Bio M&A] Even Big Pharma Companies Are Merging… But K-Bio Is Left Out of Global M&A (Part 1)
A mega-pharmaceutical company with a market capitalization of approximately $400 billion (about 570 trillion won) was on the verge of being formed. This came as AstraZeneca, a leading global pharmaceu…
Technology
Lundbeck Explores Other Indications for 'APB-A1'… "A Negative Sign, Even If Development Isn't Halted"
AprilBio Co.,Ltd.(397030)has decided to explore other indications for “APB-A1” (Lu AG22515), a technology it licensed to Lundbeck, after the compound failed to demonstrate the expected clinical effica…
Technology
U.S. FDA Approves Anticancer Virus for the First Time in 11 Years… Positive News for SillaJen, Inc.’s ‘SJ-600’
With the U.S. Food and Drug Administration (FDA) approving a new oncolytic virus therapy for the first time in about 11 years, attention in South Korea is turning to SillaJen, Inc.(215600), which is d…
Lifestyle
Remedi Surges 23%; Bio Solution Climbs on China Expansion [K-bio pulse]
Portable X-ray manufacturer Remedi saw its stock price surge after reporting explosive earnings growth. The company is expanding rapidly not only in South Korea but also overseas, raising expectations…
Lifestyle
Remedy Soars 23% on Strong Earnings… Bio Solution Co.,Ltd., Expanding into China, Also Draws Attention [Bio Spotlight]
The stock price of #Remedy, a portable X-ray company, rose sharply as the company posted explosive earnings growth. As Remedy continues to grow rapidly both domestically and internationally, it is exp…
Technology
Inbosa Faces Setbacks, Cartistem Succeeds… “Pain,” the Biggest Challenge, Determined Success or Failure
As TG-C (formerly Invossa) from Kolon TissueGene, Inc.(950160)failed to demonstrate pain relief in its U.S. Phase 3 clinical trial, “pain”—considered the biggest challenge in the development of osteoa…